Consensus Sarepta Therapeutics, Inc.

Equities

SRPT

US8036071004

Market Closed - Nasdaq Other stock markets 04:00:02 2024-05-31 pm EDT			5-day change	1st Jan Change
129.8 ^USD	+4.28%		+5.12%	+34.58%

May. 30	Sector Update: Health Care Stocks Mixed Pre-Bell Thursday	MT
May. 30	Sector Update: Health Care	MT

Evolution of the average Target Price on Sarepta Therapeutics, Inc.

Price target over the last 5 years

History of analyst recommendation changes

4996ef06782fb13487.kY4WAHYQQZVU7zzotVpnoSp_tHMrVQwt_9b4ArB5sBs.9-pPayBhC60_inCD2Rs2-Fs3gBhtEl9JyImARtQS0nWg5lRnNGIm-hmkdQ~0b2b99782cc12625c617a7d13ea0b99c

Analyst Recommendations on Sarepta Therapeutics, Inc.

Sarepta Therapeutics Shares Fall After RBC Downgrade	May. 28	MT
RBC Downgrades Sarepta Therapeutics to Sector Perform From Outperform, Lowers Price Target to $142 From $157	May. 28	MT
Mizuho Adjusts Price Target on Sarepta Therapeutics to $179 From $145, Maintains Buy Rating	May. 17	MT
Oppenheimer Upgrades Sarepta Therapeutics to Outperform From Perform, Price Target is $180	May. 14	MT
UBS Adjusts Price Target on Sarepta Therapeutics to $173 From $167, Maintains Buy Rating	May. 02	MT
Morgan Stanley Raises Price Target on Sarepta Therapeutics to $165 From $160, Keeps Overweight Rating	May. 02	MT
UBS Raises Sarepta Therapeutics Price Target to $167 From $164, Maintains Buy Rating	Mar. 01	MT
Deutsche Bank Cuts Sarepta Therapeutics Price Target to $156 From $158, Maintains Buy Rating	Feb. 29	MT
Needham Cuts Price Target on Sarepta Therapeutics to $166 From $169, Maintains Buy Rating	Feb. 29	MT
RBC Boosts Price Target on Sarepta Therapeutics to $157 From $151, Keeps Outperform Rating	Feb. 29	MT
Mizuho Adjusts Price Target on Sarepta Therapeutics to $145 From $130, Keeps Buy Rating	Feb. 14	MT
BMO Capital Starts Sarepta Therapeutics With Outperform Rating, $170 Price Target	Jan. 31	MT
RBC Trims Price Target on Sarepta Therapeutics to $151 From $155, Keeps Outperform Rating	Jan. 25	MT
Needham Raises Price Target on Sarepta Therapeutics to $140 From $93, Keeps Buy Rating	Jan. 10	MT
RBC Raises Price Target on Sarepta Therapeutics to $155 From $148, Keeps Outperform Rating	Jan. 03	MT
Deutsche Bank Initiates Coverage on Sarepta Therapeutics With Buy Rating, $109 Price Target	Dec. 12	MT
Wedbush Starts Sarepta Therapeutics With Outperform Rating, $224 PT; Says Dominance in Duchenne Muscular Dystrophy Presents Notable Commercial Hurdle to Gene Therapy Competitors	Nov. 21	MT
Wedbush Starts Sarepta Therapeutics With Outperform Rating, $224 PT; Says Dominance in Duchenne Muscular Dystrophy Presents Notable Commercial Hurdle to Gene Therapy Competitors	Nov. 21	MT
Needham Raises Price Target on Sarepta Therapeutics to $93 From $82, Keeps Buy Rating	Nov. 02	MT
Cantor Fitzgerald Downgrades Sarepta Therapeutics to Neutral From Overweight, Cuts Price Target to $40 From $166	23-10-31	MT
Morgan Stanley Adjusts Price Target on Sarepta Therapeutics to $146 From $183, Maintains Overweight Rating	23-10-31	MT
Oppenheimer Downgrades Sarepta Therapeutics to Perform From Outperform	23-10-31	MT
Needham Adjusts Sarepta Therapeutics Price Target to $82 From $185, Maintains Buy Rating	23-10-31	MT
RBC Cuts Price Target on Sarepta Therapeutics to $148 From $217, Keeps Outperform Rating	23-10-31	MT
UBS Adjusts Price Target on Sarepta Therapeutics to $174 From $173, Maintains Buy Rating	23-08-04	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

129.9 USD

Average target price

167.5 USD

Spread / Average Target

+28.96%

High Price Target

224 USD

Spread / Highest target

+72.49%

Low Price Target

128 USD

Spread / Lowest Target

-1.43%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Sarepta Therapeutics, Inc.

RBC Capital Markets
Mizuho Securities
Oppenheimer
UBS
Morgan Stanley
Deutsche Bank Securities
Needham & Co.
BMO Capital
Wedbush
Cantor Fitzgerald
JPMorgan Chase
Goldman Sachs
Citigroup
Evercore ISI
Credit Suisse
TD Cowen
Baird
Berenberg Bank
BTIG
SVB Securities LLC
Guggenheim

Ratings for Sarepta Therapeutics, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C+

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar